Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)
Anita K Gandhi, Jian Kang, Courtney G Havens, Thomas Conklin, Yuhong Ning, Lei Wu, Takumi Ito, Hideki Ando, Michelle F Waldman, Anjan Thakurta, Anke Klippel, Hiroshi Handa, Thomas O Daniel, Peter H Schafer, Rajesh Chopra, Anita K Gandhi, Jian Kang, Courtney G Havens, Thomas Conklin, Yuhong Ning, Lei Wu, Takumi Ito, Hideki Ando, Michelle F Waldman, Anjan Thakurta, Anke Klippel, Hiroshi Handa, Thomas O Daniel, Peter H Schafer, Rajesh Chopra
Abstract
Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(CRBN) . T cell co-stimulation by lenalidomide or pomalidomide is cereblon dependent: however, the CRL4(CRBN) substrates responsible for T cell co-stimulation have yet to be identified. Here we demonstrate that interaction of the transcription factors Ikaros (IKZF1, encoded by the IKZF1 gene) and Aiolos (IKZF3, encoded by the IKZF3 gene) with CRL4(CRBN) is induced by lenalidomide or pomalidomide. Each agent promotes Aiolos and Ikaros binding to CRL4(CRBN) with enhanced ubiquitination leading to cereblon-dependent proteosomal degradation in T lymphocytes. We confirm that Aiolos and Ikaros are transcriptional repressors of interleukin-2 expression. The findings link lenalidomide- or pomalidomide-induced degradation of these transcriptional suppressors to well documented T cell activation. Importantly, Aiolos could serve as a proximal pharmacodynamic marker for lenalidomide and pomalidomide, as healthy human subjects administered lenalidomide demonstrated Aiolos degradation in their peripheral T cells. In conclusion, we present a molecular model in which drug binding to cereblon results in the interaction of Ikaros and Aiolos to CRL4(CRBN) , leading to their ubiquitination, subsequent proteasomal degradation and T cell activation.
Keywords: Aiolos; Cereblon; Ikaros; lenalidomide; pomalidomide.
© 2013 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4232904/bin/bjh0164-0811-f1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4232904/bin/bjh0164-0811-f2.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4232904/bin/bjh0164-0811-f3.jpg)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4232904/bin/bjh0164-0811-f4.jpg)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4232904/bin/bjh0164-0811-f5.jpg)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4232904/bin/bjh0164-0811-f6.jpg)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4232904/bin/bjh0164-0811-f7.jpg)
![Figure 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4232904/bin/bjh0164-0811-f8.jpg)
![Figure 9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4232904/bin/bjh0164-0811-f9.jpg)
References
- Bandyopadhyay S, Duré M, Paroder M, Soto-Nieves N, Puga I. Macián F. Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. Blood. 2007;109:2878–2886.
- Billot K, Parizot C, Arrouss I, Mazier D, Debre P, Rogner UC. Rebollo A. Differential Aiolos expression in human hematopoietic subpopulations. Leukemia Research. 2010;34:289–293.
- Cai Q, Dierich A, Oulad-Abdelghani M, Chan S. Kastner P. Helios deficiency has minimal impact on T cell development and function. Journal of Immunology. 2009;183:2303–2311.
- Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R. Laskin OL. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Journal of Clinical Pharmacology. 2007;47:1466–1475.
- Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI. Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. Journal of Immunology. 1999;163:380–386.
- Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI. Dalgleish AG. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Thl-type immunity. Journal of Immunology. 2002;168:4914–4919.
- Ferreirós-Vidal I, Carroll T, Taylor B, Terry A, Liang Z, Bruno L, Dharmalingam G, Khadayate S, Cobb BS, Smale ST, Spivakov M, Srivastava P, Petretto E, Fisher AG. Merkenschlager M. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood. 2013;121:1769–1782.
- Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. Dalgleish AG. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology Immunotherapy. 2008;58:1033–1045.
- Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL. Quintana FJ. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nature Immunology. 2010;11:846–853.
- Gandhi AK, Shi T, Li M, Jungnelius U, Romano A, Tabernero J, Siena S, Schafer PH. Chopra RImmunomodulatory. Effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. PLoS ONE. 2013;8:e80437.
- Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, Soverini S, Amabile M, Poerio A, Saglio G, Pane F, Berton G, Baruzzi A, Vitale A, Chiaretti S, Perini G, Foà R, Baccarani M. Martinelli G. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood. 2008;112:3847–3855.
- Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y. Handa H. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–1350.
- Kim J, Sif S, Jones B, Jackson A, Koipally J, Heller E, Winandy S, Viel A, Sawyer A, Ikeda T. Kingst R. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity. 1999;10:345–355.
- Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ, Harper JW. Gygi SP. Systematic and quantitative assessment of the ubiquitin modified proteome. Molecular Cell. 2011;44:325–340.
- Koipally J, Renold A, Kim J. Georgopoulos K. Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO Journal. 1999;18:3090–3100.
- Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF. Chopra R. Cereblon is a direct target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–2335.
- Ma S, Pathak S, Mandal M, Trinh L, Clark MR. Lu R. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Molecular and Cellular Biology. 2010;30:4149–4158.
- Nückel H, Frey UH, Sellmann L, Collins CH, Dührsen U. Siffert W. The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia. British Journal of Haematology. 2008;144:268–270.
- Quintana FJ, Jin H, Burns EJ, Nadeau M, Yeste A, Kumar D, Rangachari M, Zhu C, Xiao S, Seavitt J, Georgopoulos K. Kuchroo VK. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nature Immunology. 2012;13:770–778.
- Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC. Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation. 2008;118:2427–2437.
- Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, Wolbring G, Govinda S, Corral LG, Payvandi F, Muller GW. Stirling DI. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. Journal of Pharmacology and Experimental Therapeutics. 2003;305:1222–1232.
- Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology. 2004;3
- Sun L, Goodman PA, Wood CM, Crotty ML, Sensel M, Sather H, Navara C, Nachman J, Steinherz PG, Gaynon PS, Seibel N, Vassilev A, Juran BD, Reaman GH. Uckun FM. Expression of aberrantly spliced oncogenic Ikaros isoforms in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology. 1999;17:3753–3766.
- Thomas RM, Chunder N, Chen C, Umetsu SE, Winandy S. Wells AD. Ikaros enforces the costimulatory requirement for IL-2 gene expression and is required for anergy induction in CD4+ T lymphocytes. Journal of Immunology. 2007;179:7305–7315.
- Thompson EC, Cobb BS, Sabbattini P, Meixlsperger S, Parelho V, Liberg D, Taylor B, Dillon N, Georgopoulos K, Jumaa H, Smale ST, Fisher AG. Merkenschlager M. Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity. 2007;26:335–344.
- Wang JH, Nichogiannopoulou A, Wu L, Sun L, Sharpe AH, Bigby M. Georgopoulos K. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity. 1996;5:537–549.
- Wang JH, Avitahl N, Cariappa A, Friedrich C, Ikeda T, Renold A, Andrikopoulos K, Liang L, Pillai S, Morgan BA. Georgopoulos K. Aiolos regulates B cell activation and maturation to effector state. Immunity. 1998;9:543–553.
- Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P. Bartlett JB. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clinical Cancer Research. 2008;14:4650–4657.
- Yang L, Luo Y. Wei J. Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. Oncology Reports. 2010;24:571–577.
- Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ. Stewart AK. Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779.
Source: PubMed